Cargando…

Influence of KDR Genetic Variation on the Efficacy and Safety of Patients with Chemotherapy Refractory Metastatic CRC Who Received Apatinib Treatment

BACKGROUND: The aim of the present study was to investigate the influence of kinase insert domain containing receptor (KDR) genetic variation on the efficacy of treatment and safety of patients with chemotherapy-refractory metastatic colorectal cancer (CRC) receiving apatinib. METHODS: A total of 10...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bai, Ming, Li, Zhi-Guo, Ba, Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006973/ https://www.ncbi.nlm.nih.gov/pubmed/33790633 http://dx.doi.org/10.2147/IJGM.S300968

Ejemplares similares

Efficacy and Safety of Apatinib in the Treatment of Chemotherapy-Refractory Metastatic Colorectal Cancer: A Systematic Review
por: Khan, Aujala Irfan, et al.
Publicado: (2022)

The Influence of KDR Genetic Variation on the Efficacy and Safety of Patients With Advanced NSCLC Receiving First-Line Bevacizumab Plus Chemotherapy Regimen
por: Geng, Nan, et al.
Publicado: (2021)

Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma
por: Yuan, Shumin, et al.
Publicado: (2022)

Apatinib treatment for KIT- and KDR-amplified angiosarcoma: a case report
por: Yang, Lishu, et al.
Publicado: (2018)

Correction to: Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma
Publicado: (2022)

Efficacy and toxicity of apatinib combined with or without chemotherapy for patients with advanced or metastatic chemotherapy-refractory gastric adenocarcinoma: A prospective clinical study
por: Guo, Yesong, et al.
Publicado: (2019)

The efficacy and safety of apatinib for refractory malignancies: a review and meta-analysis
por: Sun, Dantong, et al.
Publicado: (2018)

Safety and efficacy of apatinib combined with iodine-125 in chemotherapy-refractory advanced lung cancer: A case report
por: Zhang, Yunchao, et al.
Publicado: (2020)

The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial
por: Tang, Lin-Quan, et al.
Publicado: (2023)

A Study Of Efficacy And Safety With Apatinib Or Apatinib Combined With Chemotherapy In Recurrent/advanced Ovarian Cancer Patients
por: Yang, Mi, et al.
Publicado: (2019)

Efficacy and safety of apatinib in patients with untreated or chemotherapy-refractory soft tissue sarcoma: a multicenter, phase 2 trial
por: Yu, Wenxi, et al.
Publicado: (2022)

Clinical Outcomes and Safety of Apatinib Mesylate in the Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer in Patients Who Progressed After Standard Therapy and Analysis of the KDR Gene Polymorphism
por: Song, Zi-Zheng, et al.
Publicado: (2020)

Apatinib Monotherapy for Chemotherapy-Refractory Metastatic Colorectal Cancer: A Multi-centre, Single-Arm, Prospective Study
por: Wang, Fen, et al.
Publicado: (2020)

Assessment of the cardiac safety between cetuximab and panitumumab as single therapy in Chinese chemotherapy-refractory mCRC
por: Tang, Xue-miao, et al.
Publicado: (2017)

Activity and safety of apatinib monotherapy or apatinib combined with chemotherapy for patients with metastatic or unresectable osteosarcoma over the age of 40 years: A retrospective analysis
por: Gong, Taojun, et al.
Publicado: (2022)

Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety
por: Liao, Zhichao, et al.
Publicado: (2019)

The Efficacy and Safety of Apatinib in Refractory/Relapse Advanced Pediatric Solid Tumor: A Retrospective Study
por: Sun, Feifei, et al.
Publicado: (2020)

Apatinib in treating patients with recurrent or metastatic nasopharyngeal carcinoma who had failed prior platinum-based chemotherapy
por: Tao, Chang-Juan, et al.
Publicado: (2020)

Association of BMI with overall survival in patients with mCRC who received chemotherapy versus EGFR and VEGF-targeted therapies
por: Patel, Gargi S, et al.
Publicado: (2015)

Implication of KDR Polymorphism rs2071559 on Therapeutic Outcomes and Safety of Postoperative Patients with Gastric Cancer Who Received S-1-Based Adjuvant Chemotherapy: A Real-World Exploratory Study
por: Meng, Lei, et al.
Publicado: (2023)

Efficacy and safety of apatinib for the treatment of AFP-producing gastric cancer
por: Li, Ningning, et al.
Publicado: (2020)

Efficacy and Safety of Apatinib in Patients with Recurrent Glioblastoma
por: Lin, Hao, et al.
Publicado: (2023)

Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC)
por: Rossi, Luigi, et al.
Publicado: (2013)

The Efficacy And Safety Of Apatinib Treatment For Patients With Metastatic Or Recurrent Cervical Cancer: A Retrospective Study
por: Yu, Jiangtao, et al.
Publicado: (2019)

A Single‐Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer
por: Chen, Xiaofeng, et al.
Publicado: (2019)

Apatinib plus chemotherapy for non-metastatic osteosarcoma: a retrospective cohort study
por: Wang, Jiaqiang, et al.
Publicado: (2023)

Efficacy and Safety of Apatinib in the Treatment of Postoperative Recurrence of Fibrosarcoma
por: Ma, Huiwen, et al.
Publicado: (2020)

The efficacy and safety of apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis
por: Lin, Huixiong, et al.
Publicado: (2022)

Clinical response and safety of apatinib monotherapy in recurrent, metastatic cervical cancer after failure of chemotherapy: a retrospective study
por: Xiao, Yan, et al.
Publicado: (2019)

Efficacy and safety of apatinib in advanced refractory soft tissue sarcoma and association with histologic subtypes: a multicenter retrospective study
por: Wang, Xiangling, et al.
Publicado: (2022)

Efficacy of the Low Dose Apatinib plus Chemotherapy on Advanced Gastric Carcinoma
por: Gao, Shen, et al.
Publicado: (2022)

Efficacy and safety of apatinib in patients with previously treated metastatic colorectal cancer: a real-world retrospective study
por: Gou, Miaomiao, et al.
Publicado: (2018)

Efficacy and Safety of Apatinib Treatment for Patients with Advanced Intrahepatic Cholangiocarcinoma
por: Lin, Guohe, et al.
Publicado: (2020)

Extraordinary response of metastatic pancreatic cancer to apatinib after failed chemotherapy: A case report and literature review
por: Li, Cheng-Ming, et al.
Publicado: (2017)

Efficacy and Adverse Events of Apatinib Salvage Treatment for Refractory Diffuse Malignant Peritoneal Mesothelioma: A Pilot Study
por: Yang, Zhi-Ran, et al.
Publicado: (2022)

Feasibility of Apatinib in Radioiodine-Refractory Differentiated Thyroid Carcinoma
por: Du, Wei, et al.
Publicado: (2022)

CRC handbook of laboratory safety
Publicado: (1995)

CRC handbook of laboratory safety
Publicado: (1990)

Efficacy and safety for Apatinib treatment in advanced gastric cancer: a real world study
por: Zhang, Yong, et al.
Publicado: (2017)

Experimental study of the vascular normalization window for tumors treated with apatinib and the efficacy of sequential chemotherapy with apatinib in lung cancer‐bearing mice and patients
por: Liu, Mingtao, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0rbh1nvmd77vo5q4c11f7amjif